1
|
Manzano JL, Martin-Liberal J, Fernández-Morales LA, Benítez G, Medina Martínez J, Quindós M, García-Castaño A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías Cerrolaza JA, Gil-Arnaiz I, Lorente D, Rodriguez-Lescure A, Perez VN, López Castro R, Gramaje MG, Puértolas T, Rodriguez Moreno JF, Espasa Font L, Belaustegui Ferrández G, Cerezuela-Fuentes P. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. Melanoma Res 2023; 33:388-397. [PMID: 36988401 PMCID: PMC10470432 DOI: 10.1097/cmr.0000000000000888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 02/11/2023] [Indexed: 03/30/2023]
Abstract
BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF - V600 mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospective observational study, collected real-world data from 25 hospitals in Spain. Histologically confirmed and resected BRAF -mutated melanoma patients aged ≥18 years who were previously treated with dabrafenib plus trametinib adjuvant therapy, were included. The primary objectives were treatment discontinuation rate and time to discontinuation. The secondary objectives included safety and efficacy. From October 2020 to March 2021, 65 patients were included. Dabrafenib and trametinib discontinuation rate due to treatment-related adverse events (TRAEs) of any grade was 9%. Other reasons for discontinuation included patients' decisions (6%), physician decisions (6%), unrelated adverse events (3%), disease progression (5%), and others (5%). The median time to treatment discontinuation was 9 months [95% confidence interval (CI), 5-11]. G3-4 TRAEs occurred in 21.5% of patients, the most common being pyrexia (3%), asthenia (3%), and diarrhoea (3%). Unscheduled hospitalisations and clinical tests occurred in 6 and 22% of patients, respectively. After 20-month median follow-up (95% CI, 18-22), 9% of patients had exitus due to disease progression, with a 12-month relapse-free survival and overall survival rates of 95.3% and 100%, respectively. Dabrafenib and trametinib adjuvant therapy proved effective for melanoma patients in a real-world setting, with a manageable toxicity profile. Toxicity frequencies were low leading to low incidence of unscheduled medical visits, tests, and treatment discontinuations.
Collapse
Affiliation(s)
- José L Manzano
- Medical Oncology, Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona
| | | | | | - Gretel Benítez
- Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas
| | | | - María Quindós
- Medical Oncology, Complejo Hospitalario Universitario A Coruña, La Coruña
| | | | - Ovidio Fernández
- Medical Oncology, Complejo Hospitalario Universitario de Ourense, Orense
| | - Rocío V Simo
- Medical Oncology, Hospital Arquitecto Marcide, Ferrol
| | - Margarita Majem
- Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - Lorena Bellido
- Medical Oncology, Complejo Asistencial Universitario de Salamanca, Salamanca
| | | | - Begoña Campos
- Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo
| | - Enrique Espinosa
- Medical Oncology, Hospital Universitario La Paz - CIBERONC, Madrid
| | | | | | - David Lorente
- Medical Oncology, Hospital Provincial de Castellón, Castellón de la Plana
| | | | | | | | - María G Gramaje
- Medical Oncology, Hospital Universitario Son Llàtzer, Mallorca
| | - Teresa Puértolas
- Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza
| | | | - Laia Espasa Font
- Solid Tumours Medical Department, Novartis Farmacéutica S.A., Barcelona
| | | | - Pablo Cerezuela-Fuentes
- Medical Oncology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Ciudad de Murcia, Spain
| |
Collapse
|